About us

Home

About us

About Maxhealth Innovative Meditech

We are an innovative healthcare company providing a complete portfolio of non-invasive

diagnostic and therapeutic solutions for reflux disease.

Our Mission

To empower individuals and clinicians by simplifying reflux disease management through innovative,

non-invasive solutions that are accurate, accessible, and patient-centric.

Our Goal

To become the global partner of choice in reflux care, advancing diagnostics and treatment

to improve patient outcomes and quality of life worldwide.

Company Introduction

As a wholly-owned subsidiary of Maxhealth Medical Group (NEEQ: 836163), Maxhealth Innovative Meditech (Wuxi) Ltd is dedicated to building a comprehensive R&D and product ecosystem for gastroesophageal reflux disease (GERD).

Established in 2017, Maxhealth Innovative Meditech benefits directly from the Group's strong financial and operational backing, who was founded in Wuxi in 2009 and listed on the NEEQ in 2016. The Group owns a proprietary 65,000㎡ life science park, operates four R&D centers (two in China and two overseas), and employs over 200 professionals worldwide.With extensive experience in clinical research, academic promotion, channel development and commercialization, the Group provides a solid platform for its subsidiaries.

Leveraging this support, Maxhealth Innovative Meditech is well-positioned to accelerate its pipeline and become a globally influential leader in the digestive health field.

Our Team

Our team integrates expertise from both the UK and China, with leadership holding Ph.D. degrees in related fields. The foundation of our technology stems from the pioneering work of Prof. Peter Dettmar, a world-renowned authority in reflux disease. Below is a brief profile of Prof. Peter Dettmar:

•Honorary Professor--Department of pharmaceutical sciences at the University of Nottingham.

•R&D Director of Reckitt in UK developed gastrointestinal digestive products, such as Gaviscon range.

Our specialists, with diverse backgrounds in clinical medicine, pharmacy, and bioengineering, collaborate across borders to drive innovation. Together, we are focused exclusively on advancing and delivering precise solutions in reflux management.

Our Qualification

We are certified as a National High-Tech Enterprise and hold a portfolio of over 40 patents. Our flagship diagnostic products have obtained key market authorizations, including NMPA (China), CE (EU), and FDA (USA) clearances. The company's quality management system is certified to ISO 13485 standards, ensuring excellence from development to production.